Arjo AB (publ) (ARRJF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arjo AB (publ) (ARRJF) trades at $2.55 with AI Score 43/100 (Grade C). Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges. Market cap: $694.54M, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for ARRJF: ARRJF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARRJF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ARRJF: the 1 perspectives are evenly split.
How is this calculated? →Arjo AB (publ) (ARRJF) Healthcare & Pipeline Overview
Arjo AB (publ) is a global medical device company focused on providing solutions for patients with reduced mobility and age-related health challenges. With a presence in North America, Western Europe, and other international markets, Arjo offers a comprehensive portfolio of products and services for acute and long-term care facilities.
What Is the Investment Thesis for ARRJF?
Arjo AB (publ) presents a notable research candidate driven by the increasing global demand for healthcare solutions for aging populations and patients with reduced mobility. With a current P/E ratio of 19.0 and a dividend yield of 3.67%, the company offers a blend of value and income potential. Growth catalysts include expansion into emerging markets and the introduction of innovative products addressing unmet needs in patient care. The company's strong market position and established distribution network provide a solid foundation for future growth. However, investors should be aware of potential risks such as increased competition and regulatory changes in the healthcare industry. Arjo's ability to maintain its profit margin of 3.0% and capitalize on growth opportunities will be crucial for long-term success.
Based on FMP financials and quantitative analysis
ARRJF Key Highlights
- Market capitalization of $694.54M reflects Arjo's established presence in the medical device market.
- P/E ratio of 19.0 indicates a reasonable valuation compared to its earnings.
- Gross margin of 40.9% demonstrates Arjo's ability to maintain profitability in a competitive market.
- Dividend yield of 3.67% provides an attractive income stream for investors.
- Beta of 0.77 suggests lower volatility compared to the overall market.
Who Are ARRJF's Competitors?
ARRJF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EXETF Extendicare Inc. | $26.14 | +1.40% | $2.48B | 54 |
| LFTSF LifeTech Scientific Corporation | $0.20 | -16.49% | $858.15M | 63 |
| NNCSF Nanosonics Limited | $2.07 | -18.82% | $618.75M | 54 |
| PHCI Panamera Holdings Corporation | $2.50 | +0.00% | $184.72M | 54 |
| RKAGY RHON-KLINIKUM AG Unsponsored ADR | $8.16 | +0.00% | $1.09B | 52 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARRJF's Key Strengths?
- Strong brand reputation and established market presence.
- Comprehensive product portfolio addressing diverse patient needs.
- Extensive distribution network across key geographic markets.
- Focus on innovation and customer satisfaction.
What Are ARRJF's Weaknesses?
- Relatively low profit margin compared to industry peers.
- Dependence on healthcare spending and reimbursement policies.
- Exposure to currency fluctuations and economic cycles.
- Limited presence in emerging markets compared to larger competitors.
What Could Drive ARRJF Stock Higher?
- Launch of new product lines targeting specific patient needs in Q4 2026.
- Expansion of distribution network in emerging markets throughout 2026.
- Strategic partnerships with healthcare providers to enhance service offerings.
- Publication of clinical trial results demonstrating the efficacy of Arjo's solutions in Q3 2026.
What Are the Key Risks for ARRJF?
- Increased competition from established and emerging players in the medical device industry.
- Stringent regulatory requirements and evolving industry standards.
- Economic downturns and healthcare budget cuts impacting demand for Arjo's products.
- Currency fluctuations affecting revenue and profitability.
- Dependence on key suppliers and potential supply chain disruptions.
What Are the Growth Opportunities for ARRJF?
- Expansion into emerging markets: Arjo has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is rapidly developing and the demand for advanced medical devices is increasing. By establishing strategic partnerships and tailoring its product offerings to local needs, Arjo can tap into new revenue streams and accelerate its growth trajectory. This expansion could target a market size of $10 billion by 2030.
- Development of innovative products: Arjo can invest in research and development to create innovative products that address unmet needs in patient care. By focusing on areas such as pressure injury prevention, infection control, and mobility assistance, Arjo can differentiate itself from competitors and capture a larger share of the market. Launching two new product lines annually could increase revenue by 15% by 2028.
- Strategic acquisitions: Arjo can pursue strategic acquisitions to expand its product portfolio, enhance its geographic reach, and gain access to new technologies. By acquiring complementary businesses, Arjo can strengthen its competitive position and create synergies that drive growth. Targeting acquisitions of companies with revenues between $50 million and $100 million annually could add 10% to revenue by 2027.
- Enhancement of service offerings: Arjo can enhance its service offerings, such as clinical consulting, maintenance, and equipment rental, to provide added value to its customers. By offering comprehensive solutions that address the entire patient care continuum, Arjo can strengthen its customer relationships and generate recurring revenue streams. Increasing service revenue by 20% annually could stabilize and increase profit margins by 2029.
- Digitalization of healthcare solutions: Arjo can leverage digital technologies to enhance its healthcare solutions and improve patient outcomes. By developing connected devices, data analytics platforms, and remote monitoring systems, Arjo can provide real-time insights and personalized care recommendations. Integrating AI-powered solutions could improve efficiency by 10% by 2028.
What Opportunities Does ARRJF Have?
- Expansion into emerging markets with growing healthcare demand.
- Development of innovative products and digital healthcare solutions.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Enhancement of service offerings to generate recurring revenue streams.
What Threats Does ARRJF Face?
- Increased competition from established and emerging players.
- Stringent regulatory requirements and evolving industry standards.
- Potential disruptions from technological advancements and new business models.
- Economic downturns and healthcare budget cuts.
What Are ARRJF's Competitive Advantages?
- Established brand reputation in the medical device industry.
- Comprehensive product portfolio addressing a wide range of patient needs.
- Extensive distribution network across North America, Western Europe, and other international markets.
- Strong relationships with key customers in the healthcare sector.
What Does ARRJF Do?
Founded in 1957 and headquartered in Malmö, Sweden, Arjo AB (publ) has evolved into a leading provider of medical devices and solutions catering to patients with mobility issues and age-related conditions. The company's comprehensive product portfolio includes patient handling equipment, hygiene solutions, disinfection systems, medical beds, and solutions for pressure injury prevention and treatment. Arjo also offers products for deep vein thrombosis prevention, edema treatment, obstetric diagnostics, and cardiac diagnostics. Arjo serves a diverse range of customers, including private and public institutions providing acute and long-term care. Its solutions are designed to improve patient outcomes, enhance caregiver efficiency, and promote a safe and comfortable environment. The company's geographic reach extends across North America, Western Europe, and other international markets, reflecting its commitment to serving a global customer base. Arjo's dedication to innovation and customer satisfaction has solidified its position as a trusted partner in the healthcare industry.
What Products and Services Does ARRJF Offer?
- Develops and sells medical devices for patients with reduced mobility.
- Offers solutions for age-related health challenges.
- Provides patient handling equipment and hygiene solutions.
- Manufactures and distributes medical beds and disinfection systems.
- Offers products for pressure injury and leg ulcer treatment and prevention.
- Provides solutions for deep vein thrombosis prevention and edema treatment.
- Offers obstetric and cardiac diagnostic equipment.
- Provides clinical consulting, maintenance, and equipment rental services.
How Does ARRJF Make Money?
- Develops and manufactures medical devices and solutions.
- Sells products and services to private and public healthcare institutions.
- Generates revenue through product sales, service contracts, and equipment rentals.
- Focuses on providing comprehensive solutions for patient care.
What Industry Does ARRJF Operate In?
Arjo AB (publ) operates within the medical device industry, which is experiencing steady growth driven by an aging global population and increasing demand for healthcare services. The market for patient handling and mobility solutions is particularly robust, with a growing emphasis on improving patient safety and caregiver efficiency. Arjo competes with companies like EXETF, LFTSF, NNCSF, PHCI, and RKAGY, focusing on innovation and customer service to maintain its competitive edge. The industry is subject to stringent regulatory requirements and evolving technological advancements, requiring companies to adapt and innovate to remain competitive.
Who Are ARRJF's Key Customers?
- Private hospitals and clinics
- Public healthcare institutions
- Long-term care facilities
- Rehabilitation centers
Arjo AB (publ) (ARRJF) Valuation Context
Valued at $694.54M, ARRJF is classified as a small-cap stock. Relative to its peer group, ARRJF's quantitative score of 43/100 is below the peer average of 55/100.
ARRJF Revenue & Earnings Trend
In Q1 2026, ARRJF generated $2.69B in top-line revenue, marking a sequential decrease of 4.4%. The company recorded net income of $107.6M, with diluted EPS of $0.40. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ARRJF averaged $0.33 in diluted EPS.
Company Profile
Arjo AB (publ) operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Malmö, SE. The company is led by CEO Andreas Elgaard. ARRJF has traded publicly since 2018.
ROE 5%Key Financial Metrics
Return on equity for Arjo AB (publ) stands at 4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.3%, showing how much profit it generates from its asset base. ARRJF trades at a trailing price-to-earnings ratio of 19.01, below the Healthcare sector average of ~23x. Its free cash flow yield is 16.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Arjo AB (publ)'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.13 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Arjo AB (publ) revenue of about $11.03B for fiscal 2026, with EPS near $1.81. The estimate reflects 5 contributing analysts.
ARRJF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Arjo's recent insider buying suggests those in the know see long-term value, signaling confidence despite current market conditions. Think of it like Buffett buying more Berkshire – a strong internal endorsement.
- Community sentiment shows increasing belief in Arjo's long-term growth potential within the medical technology sector, specifically regarding patient handling solutions. This rising optimism can drive demand.
- Arjo's focus on innovative healthcare solutions positions them well to capitalize on the aging global population and increasing demand for advanced medical equipment. This is similar to how Intuitive Surgical benefited from robotic surgery adoption.
- Positive market perception of Arjo's strategic partnerships and acquisitions indicates a strengthening market position and expanded reach. These moves could unlock new revenue streams and market share.
Bear Case
- Recent bearish community sentiment highlights concerns about increased competition in the medical device market, potentially impacting Arjo's market share and profitability. This is reminiscent of how generic drug manufacturers challenge established brands.
- Negative market perception surrounding potential regulatory hurdles for Arjo's new products could delay market entry and impact revenue projections. Similar to how some biotech companies face FDA approval delays.
- Insider selling activity, although not always indicative of negative sentiment, can create uncertainty among investors and potentially trigger a sell-off. This is similar to how some view Musk selling Tesla shares.
- Concerns about the impact of global economic slowdown on healthcare spending could negatively affect Arjo's sales and profitability, especially in price-sensitive markets. This is similar to how cyclical industries like automotive suffer during recessions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.69B | $108M | $0.40 |
| Q4 2025 | $2.81B | $70M | $0.26 |
| Q3 2025 | $2.63B | $80M | $0.30 |
| Q2 2025 | $2.68B | $92M | $0.34 |
Based on FMP financials and quantitative analysis
ARRJF Latest News
No recent news available for ARRJF.
ARRJF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARRJF.
Price Targets
Wall Street price target analysis for ARRJF.
ARRJF MoonshotScore
What does this score mean?
The MoonshotScore rates ARRJF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Andreas Elgaard
CEO
Andreas Elgaard is the CEO of Arjo AB (publ). He brings extensive experience in the healthcare industry, with a proven track record of driving growth and innovation. Prior to joining Arjo, Andreas held leadership positions at various medical device companies, where he focused on developing and commercializing innovative healthcare solutions. He holds an MBA from a leading business school and a degree in engineering.
Track Record: Under Andreas Elgaard's leadership, Arjo has focused on expanding its global presence and strengthening its product portfolio. He has overseen the launch of several new products and services, and has implemented strategic initiatives to improve operational efficiency and enhance customer satisfaction. His focus on innovation and customer-centricity has contributed to Arjo's continued success in the competitive healthcare market.
ARRJF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arjo AB (publ) may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be less frequent and transparent compared to exchange-listed companies. This tier is often associated with higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise caution and conduct thorough due diligence before investing in companies trading on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Potential for price volatility and manipulation.
- Higher risk of fraud or misrepresentation.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Monitor trading activity and price movements.
- Established history of operations since 1957.
- Presence in North America, Western Europe, and internationally.
- Positive analyst coverage and industry recognition.
- Commitment to innovation and customer satisfaction.
Arjo AB (publ) Healthcare Stock: Key Questions Answered
What does Arjo AB (publ) do?
Arjo AB (publ) is a global medical device company specializing in solutions for patients with reduced mobility and age-related health challenges. The company develops, manufactures, and sells a wide range of products, including patient handling equipment, hygiene solutions, medical beds, and solutions for pressure injury prevention and treatment. Arjo serves private and public healthcare institutions, providing comprehensive solutions to improve patient outcomes and enhance caregiver efficiency. Its focus on innovation and customer satisfaction has established it as a trusted partner in the healthcare industry.
What do analysts say about ARRJF stock?
Analyst consensus on ARRJF stock is mixed, with some highlighting the company's growth potential in emerging markets and its strong product portfolio. Key valuation metrics, such as the P/E ratio and dividend yield, suggest a reasonable valuation compared to its earnings and income potential. However, analysts also note potential risks, such as increased competition and regulatory changes in the healthcare industry. Investors should carefully consider these factors and conduct their own due diligence before making any investment decisions.
What are the main risks for ARRJF?
The main risks for ARRJF include increased competition in the medical device industry, which could put pressure on pricing and market share. Stringent regulatory requirements and evolving industry standards could also pose challenges for Arjo, requiring significant investments in compliance and innovation. Economic downturns and healthcare budget cuts could impact demand for Arjo's products and services. Additionally, currency fluctuations could affect revenue and profitability, particularly in international markets. Dependence on key suppliers and potential supply chain disruptions could also disrupt Arjo's operations.
What are the key factors to evaluate for ARRJF?
Arjo AB (publ) (ARRJF) holds an AI score of 43/100 (low). P/E: 19.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ARRJF data refresh on this page?
ARRJF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARRJF's recent stock price performance?
Arjo AB (publ) (ARRJF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation and established market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARRJF overvalued or undervalued right now?
Arjo AB (publ) (ARRJF) trades at 19.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ARRJF?
Before investing in Arjo AB (publ) (ARRJF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to OTC status.
- Analyst opinions may vary.